Raltegravir

Generic Name
Raltegravir
Brand Names
Isentress
Drug Type
Small Molecule
Chemical Formula
C20H21FN6O5
CAS Number
518048-05-0
Unique Ingredient Identifier
22VKV8053U
Background

Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.

Indication

For the treatment of HIV-1 infection in conjunction with other antiretrovirals.

Associated Conditions
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Associated Therapies
Post-exposure prophylaxis for occupational exposure to HIV therapy
Clinical Trials
Related News

Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults

Phase 2
Completed
Conditions
HIV-1 Infections
Interventions
Drug: Raltegravir
Drug: Darunavir/Ritonavir
First Posted Date
2009-01-28
Last Posted Date
2018-11-08
Lead Sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Target Recruit Count
113
Registration Number
NCT00830804
Locations
🇺🇸

Beth Israel Deaconess Med Center, Boston, Massachusetts, United States

🇺🇸

MetroHealth CRS, Cleveland, Ohio, United States

🇺🇸

Univ. of Cincinnati CRS, Cincinnati, Ohio, United States

and more 19 locations

Efficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis

Phase 2
Completed
Conditions
HIV Infections
Tuberculosis
Interventions
Drug: efavirenz
Drug: raltegravir
First Posted Date
2009-01-14
Last Posted Date
2013-07-17
Lead Sponsor
ANRS, Emerging Infectious Diseases
Target Recruit Count
155
Registration Number
NCT00822315
Locations
🇧🇷

Ipec/Fiocruz, Rio de Janeiro, Brazil

🇧🇷

Hospitral Universitario Pr Edgar Santos, Salvador da Bahia, Brazil

🇫🇷

Hôpital Saint-Louis, Paris, France

and more 6 locations

Pilot Study of a Raltegravir Based NRTI Sparing Regimen

First Posted Date
2008-12-25
Last Posted Date
2016-02-04
Lead Sponsor
Yale University
Target Recruit Count
60
Registration Number
NCT00814879
Locations
🇺🇸

Saint Raphael Healthcare System, New Haven, Connecticut, United States

🇺🇸

Waterbury Hospital, Waterbury, Connecticut, United States

🇺🇸

VA CT Healthcare Systems, West Haven, Connecticut, United States

and more 2 locations

Comparative Study of Three NNRTI-Sparing HAART Regimens

First Posted Date
2008-12-19
Last Posted Date
2014-09-05
Lead Sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Target Recruit Count
1814
Registration Number
NCT00811954
Locations
🇺🇸

The Ponce de Leon Center CRS, Atlanta, Georgia, United States

🇺🇸

The Ohio State Univ. AIDS CRS, Columbus, Ohio, United States

🇺🇸

Trinity Health and Wellness Center, Dallas, Texas, United States

and more 54 locations

Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine

First Posted Date
2008-12-15
Last Posted Date
2020-01-31
Lead Sponsor
Germans Trias i Pujol Hospital
Target Recruit Count
30
Registration Number
NCT00808002
Locations
🇪🇸

Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain

🇪🇸

Hospital Clinic i Provincial de Barcelona, Barcelona, Spain

Effect Of An Integrase Inhibitor On The Latency And Reservoir Of HIV-1

Phase 2
Completed
Conditions
HIV-1
HIV Infections
Interventions
Drug: Raltegravir
First Posted Date
2008-12-12
Last Posted Date
2013-02-01
Lead Sponsor
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Target Recruit Count
10
Registration Number
NCT00807443
Locations
🇪🇸

Hospital Universitario Ramon Y Cajal, Madrid, Spain

An Interaction Study to Assess Drug Levels in Fasting Healthy Adult Subjects

Not Applicable
Completed
Conditions
Healthy
Interventions
Drug: Raltegravir
Drug: Fosamprenavir
Drug: Ritonavir
First Posted Date
2008-12-04
Last Posted Date
2016-01-29
Lead Sponsor
Garden State Infectious Disease Associates, PA
Target Recruit Count
45
Registration Number
NCT00802074
Locations
🇺🇸

Garden State Infectious Disease Associates, PA, Voorhees, New Jersey, United States

Drug Interaction Study Between Raltegravir And UK-453,061

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: UK-453,061
Drug: Raltegravir
First Posted Date
2008-11-04
Last Posted Date
2008-11-18
Lead Sponsor
Pfizer
Target Recruit Count
18
Registration Number
NCT00784420
Locations
🇺🇸

Pfizer Investigational Site, New Haven, Connecticut, United States

Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1

First Posted Date
2008-10-28
Last Posted Date
2013-08-12
Lead Sponsor
University of Washington
Target Recruit Count
10
Registration Number
NCT00781287
Locations
🇺🇸

University of Washington Primary Infection Clinic, Seattle, Washington, United States

Pilot Opened Trial in HIV-infected Patients Including an Investigational Marketed Product

Phase 4
Completed
Conditions
HIV Infections
Interventions
Drug: raltegravir
First Posted Date
2008-10-16
Last Posted Date
2015-03-11
Lead Sponsor
Germans Trias i Pujol Hospital
Target Recruit Count
57
Registration Number
NCT00773708
Locations
🇪🇸

H.U. Germans Trias i Pujol, Badalona, Barcelona, Spain

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy